HUP0203568A2 - Vírusellenes készítmények - Google Patents

Vírusellenes készítmények

Info

Publication number
HUP0203568A2
HUP0203568A2 HU0203568A HUP0203568A HUP0203568A2 HU P0203568 A2 HUP0203568 A2 HU P0203568A2 HU 0203568 A HU0203568 A HU 0203568A HU P0203568 A HUP0203568 A HU P0203568A HU P0203568 A2 HUP0203568 A2 HU P0203568A2
Authority
HU
Hungary
Prior art keywords
antiviral compounds
mixture
melt
antiviral compositions
milling
Prior art date
Application number
HU0203568A
Other languages
English (en)
Inventor
Lieven Baert
Geert Verreck
Original Assignee
Janssen Pharmaceutica N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica N.V. filed Critical Janssen Pharmaceutica N.V.
Publication of HUP0203568A2 publication Critical patent/HUP0203568A2/hu
Publication of HUP0203568A3 publication Critical patent/HUP0203568A3/hu
Publication of HU228449B1 publication Critical patent/HU228449B1/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Abstract

A találmány vírusellenes vegyületeket tartalmazó gyógyászatikészítményekre vonatkozik, amelyek vírusfertőzéstől szenvedő emlősnek,közelebbről embernek adagolhatók. Ezek a készítmények olyanrészecskéket tartalmaznak, amelyek egy vagy több meghatározottvírusellenes vegyület és egy vagy több megfelelő, vízoldható polimerkeverékének ömledék-extrudálásával, és azt követően az ömledék-extrudált keverék őrlésével vannak előállítva. Ó
HU0203568A 1999-09-24 2000-08-31 Antiviral compositions HU228449B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99203128 1999-09-24
PCT/EP2000/008522 WO2001022938A1 (en) 1999-09-24 2000-08-31 Antiviral compositions

Publications (3)

Publication Number Publication Date
HUP0203568A2 true HUP0203568A2 (hu) 2003-02-28
HUP0203568A3 HUP0203568A3 (en) 2006-07-28
HU228449B1 HU228449B1 (en) 2013-03-28

Family

ID=8240674

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0203568A HU228449B1 (en) 1999-09-24 2000-08-31 Antiviral compositions

Country Status (35)

Country Link
US (4) US7241458B1 (hu)
EP (1) EP1225874B1 (hu)
JP (1) JP4919566B2 (hu)
KR (2) KR100785360B1 (hu)
CN (1) CN1234347C (hu)
AP (1) AP1639A (hu)
AT (1) ATE316781T1 (hu)
AU (2) AU775360B2 (hu)
BG (1) BG65754B1 (hu)
BR (1) BRPI0014271B1 (hu)
CA (1) CA2384188C (hu)
CY (1) CY1105268T1 (hu)
CZ (1) CZ300712B6 (hu)
DE (1) DE60025837T2 (hu)
DK (1) DK1225874T3 (hu)
EA (1) EA005423B1 (hu)
EE (1) EE04991B1 (hu)
ES (1) ES2258018T3 (hu)
HK (1) HK1048768B (hu)
HR (1) HRP20020247B1 (hu)
HU (1) HU228449B1 (hu)
IL (1) IL148801A0 (hu)
IS (1) IS2567B (hu)
MX (1) MXPA02003182A (hu)
NO (1) NO333358B1 (hu)
NZ (1) NZ517025A (hu)
OA (1) OA12029A (hu)
PL (1) PL207590B1 (hu)
PT (1) PT1225874E (hu)
SI (1) SI1225874T1 (hu)
SK (1) SK285240B6 (hu)
TR (1) TR200200763T2 (hu)
UA (1) UA74797C2 (hu)
WO (1) WO2001022938A1 (hu)
ZA (1) ZA200202289B (hu)

Families Citing this family (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1218360B1 (en) 1999-10-07 2008-05-28 Amgen Inc., Triazine kinase inhibitors
JP5767429B2 (ja) 1999-11-12 2015-08-19 アッヴィ・インコーポレイテッド 固体分散剤中の結晶化阻害剤
CA2400447C (en) 2000-02-17 2008-04-22 Amgen Inc. Kinase inhibitors
DE10026698A1 (de) 2000-05-30 2001-12-06 Basf Ag Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
WO2002068398A1 (en) 2001-02-27 2002-09-06 Teva Pharmaceutical Industries Ltd. New crystal forms of lamotrigine and processes for their preparations
CA2450957A1 (en) 2001-06-22 2003-01-03 Pfizer Products Inc. Pharmaceutical compositions of dispersions of drugs and neutral polymers
US7638522B2 (en) 2001-08-13 2009-12-29 Janssen Pharmaceutica N.V. Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino] benzonitrile
JO3429B1 (ar) 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
US8101629B2 (en) 2001-08-13 2012-01-24 Janssen Pharmaceutica N.V. Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
US6939874B2 (en) 2001-08-22 2005-09-06 Amgen Inc. Substituted pyrimidinyl derivatives and methods of use
US7115617B2 (en) 2001-08-22 2006-10-03 Amgen Inc. Amino-substituted pyrimidinyl derivatives and methods of use
EP2332924A1 (de) 2001-10-17 2011-06-15 Boehringer Ingelheim Pharma GmbH & Co. KG Pyrimidinderivate, Arzneimittel enthaltend diese Verbindungen, deren Verwendung und Verfahren zu ihrer Herstellung
SE0104140D0 (sv) 2001-12-07 2001-12-07 Astrazeneca Ab Novel Compounds
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
PT1479397E (pt) 2002-02-05 2011-09-01 Astellas Pharma Inc Derivados de 2,4,6-triamino-1,3,5-triazina
CA2483103A1 (en) * 2002-04-23 2003-11-06 Teva Pharmaceutical Industries Ltd. Pharmaceutical composition containing lamotrigine particles of defined morphology
AR039540A1 (es) * 2002-05-13 2005-02-23 Tibotec Pharm Ltd Compuestos microbicidas con contenido de pirimidina o triazina
AU2003249369A1 (en) 2002-06-21 2004-01-06 Cellular Genomics, Inc. Certain amino-substituted monocycles as kinase modulators
NZ537752A (en) 2002-07-29 2006-12-22 Rigel Pharmaceuticals Inc Use of 2,4-pyrimidinediamine compounds in the preparation of medicaments for treating autoimmune diseases
KR101140785B1 (ko) 2002-08-09 2012-05-03 얀센 파마슈티카 엔.브이. 4-〔〔4-〔〔4-（2-시아노에테닐）-2,6-디메틸페닐〕아미노〕-2-피리미디닐〕아미노〕벤조니트릴의 제조방법
WO2004026283A1 (en) * 2002-09-20 2004-04-01 Alpharma, Inc. Sequestering subunit and related compositions and metohds
RS20050363A (en) * 2002-11-28 2007-11-15 Schering Aktiengesellschaft, Chk-,pdk-and akt-inhibitory pyrimidines,their production an use as pharmaceutical agents
WO2004050068A1 (en) 2002-11-29 2004-06-17 Janssen Pharmaceutica N.V. Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base
US8293751B2 (en) 2003-01-14 2012-10-23 Arena Pharmaceuticals, Inc. 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia
PL227577B1 (pl) 2003-02-07 2017-12-29 Janssen Pharmaceutica Nv Zastosowanie pochodnych pirymidyny do wytwarzania leku do zapobiegania zakażeniu wirusem HIV oraz kompozycja farmaceutyczna
CL2004000303A1 (es) * 2003-02-20 2005-04-08 Tibotec Pharm Ltd Compuestos derivados de pirimidinas y triazinas; proceso de preparacion; composicion farmaceutica; y su uso para inhibir la replicacion del vih.
EP1648467B1 (en) 2003-07-17 2018-03-21 Janssen Sciences Ireland UC Process for preparing particles containing an antiviral
ES2421139T3 (es) 2003-07-30 2013-08-29 Rigel Pharmaceuticals, Inc. Compuestos de 2,4-pirimidindiamina para su uso en el tratamiento o la prevención de enfermedades autoinmunitarias
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US7579349B2 (en) 2003-10-17 2009-08-25 Astrazeneca Ab 4-(pyrazol-3-ylamino) pyrimidine derivatives for use in the treatment of cancer
EP2343282B1 (en) 2004-03-05 2015-07-22 F. Hoffmann-La Roche AG Diaminopyrimidines as P2X3 and P2X2/3 antagonists
BRPI0515505A (pt) 2004-09-20 2008-07-29 Xenon Pharmaceuticals Inc derivados heterocìclicos e sua utilização como inibidores da estearoil-coa desaturase
AR051090A1 (es) 2004-09-20 2006-12-20 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa
US8071603B2 (en) 2004-09-20 2011-12-06 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
EP1814551A2 (en) 2004-09-20 2007-08-08 Xenon Pharmaceuticals Inc. Pyridazine derivatives for inhibiting human stearoyl-coa-desaturase
CA2580844A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as mediators of stearoyl-coa desaturase
AR051026A1 (es) 2004-09-20 2006-12-13 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa
US7592343B2 (en) 2004-09-20 2009-09-22 Xenon Pharmaceuticals Inc. Pyridazine-piperazine compounds and their use as stearoyl-CoA desaturase inhibitors
US7557207B2 (en) 2004-11-24 2009-07-07 Rigel Pharmaceuticals, Inc. Spiro 2,4-pyrimidinediamine compounds and their uses
ES2337496T3 (es) 2005-01-19 2010-04-26 Rigel Pharmaceuticals, Inc. Profarmacos de compuestos de 2,4-pirimidindiamina y sus usos.
SI1853588T1 (sl) 2005-02-16 2008-10-31 Astrazeneca Ab Kemične spojine
MX2007010051A (es) * 2005-02-18 2007-09-21 Tibotec Pharm Ltd Derivados de oxido de 2-(4-cianofenilamino)pirimidina que inhiben el virus de inmunodeficiencia humana.
ATE473212T1 (de) * 2005-03-04 2010-07-15 Tibotec Pharm Ltd Hiv-inhibierende 2-(4-cyanophenyl)-6- hydroxylaminopyrimidine
TW200710091A (en) 2005-04-11 2007-03-16 Tibotec Pharm Ltd (1,10B-dihydro-2-(aminoalkyl-phenyl)-5H-pyrazolo [1,5-c][1,3]benzoxazin-5-yl)phenyl methanone derivatives as HIV viral replication inhibitors
JP2008540622A (ja) 2005-05-16 2008-11-20 アストラゼネカ アクチボラグ 化合物
PT1888537E (pt) * 2005-05-26 2013-11-26 Janssen R & D Ireland Processo para preparar 4-[(1,6-dihidro-6-oxo-2-pirimidinil)amino benzonitrilo
AU2006343359A1 (en) 2005-06-03 2007-11-15 Xenon Pharmaceuticals Inc. Aminothiazole derivatives as human stearoyl-coa desaturase inhibitors
EP1924565B1 (en) 2005-09-01 2016-09-14 F.Hoffmann-La Roche Ag Diaminopyrimidines as p2x3 and p3x2/3 modulators
CA2619919C (en) 2005-09-01 2014-04-01 F. Hoffmann-La Roche Ag Diaminopyrimidines as p2x3 and p2x2/3 modulators
JP4850913B2 (ja) 2005-09-01 2012-01-11 エフ．ホフマン−ラ ロシュ アーゲー Ｐ２ｘ３及びｐ２ｘ２／３調節因子としてのジアミノピリジン
WO2007049041A1 (en) 2005-10-28 2007-05-03 Astrazeneca Ab 4- (3-aminopyrazole) pyrimidine derivatives for use as tyrosine kinase inhibitors in the treatment of cancer
JP2009514884A (ja) * 2005-11-04 2009-04-09 イーストマン ケミカル カンパニー 難溶性医薬活性剤の投与のためのカルボキシアルキルセルロースエステル
ATE522202T1 (de) 2006-06-06 2011-09-15 Tibotec Pharm Ltd Verfahren zur herstellung von sprühgetrockneten formulierungen von tmc125
PL2526932T3 (pl) 2006-06-19 2017-12-29 Alpharma Pharmaceuticals Llc Kompozycja farmaceutyczna
CA2665726C (en) * 2006-10-11 2016-04-19 Alpharma, Inc. Pharmaceutical compositions
WO2008068299A2 (en) * 2006-12-06 2008-06-12 Tibotec Pharmaceuticals Ltd. Hydrobromide salt of an anti-hiv compound
TWI494133B (zh) * 2007-03-14 2015-08-01 Tibotec Pharm Ltd 重組用粉末
UA99459C2 (en) 2007-05-04 2012-08-27 Астразенека Аб 9-(pyrazol-3-yl)- 9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidazo[4,5-b]pyridin-5-amine derivatives and their use for the treatment of cancer
WO2008154234A2 (en) * 2007-06-08 2008-12-18 Boehringer Ingelheim International Gmbh Extended release formulation of nevirapine
CA2689330A1 (en) * 2007-06-25 2008-12-31 Tibotec Pharmaceuticals Combination formulations
US8410124B2 (en) * 2007-10-18 2013-04-02 Concert Pharmaceuticals Inc. Deuterated etravirine
JP5600063B2 (ja) 2007-10-19 2014-10-01 セルジーン アビロミクス リサーチ， インコーポレイテッド ヘテロアリール化合物およびその使用
US7989465B2 (en) * 2007-10-19 2011-08-02 Avila Therapeutics, Inc. 4,6-disubstituted pyrimidines useful as kinase inhibitors
US20090196890A1 (en) * 2007-12-17 2009-08-06 Alpharma Pharmaceuticals, Llc Pharmaceutical compositions
US8623418B2 (en) 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
CA2734489C (en) * 2008-08-20 2016-11-08 Southern Research Institute Ethenyl-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
TW201020245A (en) * 2008-08-20 2010-06-01 Schering Corp Ethynyl-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
US20110195912A1 (en) * 2008-09-17 2011-08-11 Nektar Therapeutics Oligomer-Protease Inhibitor Conjugates
CN101744823B (zh) * 2008-12-17 2013-06-19 广东东阳光药业有限公司 一种二氢嘧啶类化合物的固体分散体及其药用制剂
CA2757228C (en) 2009-03-30 2018-01-02 Tibotec Pharmaceuticals Co-crystal of etravirine and nicotinamide
JP2012529512A (ja) * 2009-06-08 2012-11-22 アブラクシス バイオサイエンス リミテッド ライアビリティー カンパニー トリアジン誘導体類及びそれらの治療応用
EP2342186B1 (en) * 2009-06-22 2014-09-17 Emcure Pharmaceuticals Limited Process for synthesis of etravirine
JP5713367B2 (ja) 2010-06-04 2015-05-07 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｌｒｒｋ２モジュレーターとしてのアミノピリミジン誘導体
CA2812061A1 (en) 2010-09-22 2012-03-29 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
BR112013011600B1 (pt) 2010-11-10 2022-01-11 Genentech, Inc Derivados de pirazol aminopirimidina, seu uso e composição que os compreende
WO2012088266A2 (en) 2010-12-22 2012-06-28 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
PT2836559T (pt) * 2012-04-11 2016-08-31 Dow Global Technologies Llc Composição que compreende um diluente orgânico e um éter de celulose.
BR112014020719B1 (pt) * 2012-04-11 2020-03-03 Dow Global Technologies Llc Forma de dosagem de liberação constante, método para preparar uma forma de dosagem de liberação constante e uso de um éter de celulose
BR112014020718B1 (pt) 2012-04-11 2020-11-17 Dow Global Technologies Llc composição polimérica extrusada sob fusão, processo para produzir uma composição polimérica extrusada sob fusão e uso de pelo menos um éter de celulose
IL289834B1 (en) 2012-06-13 2024-03-01 Incyte Holdings Corp Conversion of tricyclic compounds as FGFR inhibitors
EP2872492B1 (en) * 2012-07-12 2018-01-31 Hetero Research Foundation Process for the preparation of rilpivirine using a novel intermediate
US9388185B2 (en) 2012-08-10 2016-07-12 Incyte Holdings Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
SG10201708520YA (en) 2013-04-19 2017-12-28 Incyte Corp Bicyclic heterocycles as fgfr inhibitors
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
MX2021011472A (es) 2015-01-06 2022-08-17 Arena Pharm Inc Metodos de condiciones de tratamiento relacionadas con el receptor s1p1.
MX2017010673A (es) 2015-02-20 2018-03-21 Incyte Corp Heterociclos biciclicos como inhibidores de receptores del factor de crecimiento fibroblastico (fgfr).
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
US9580423B2 (en) 2015-02-20 2017-02-28 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
AR100459A1 (es) * 2015-05-15 2016-10-05 Química Luar S R L Una composición farmacéutica antiviral de uso tópico
MA42807A (fr) 2015-06-22 2018-07-25 Arena Pharm Inc Sel l-arginine cristallin d'acide (r)-2-(7-(4-cyclopentyl-3-(trifluorométhyl)benzyloxy)-1,2,3,4-tétrahydrocyclo-penta[b]indol-3-yl)acétique (composé 1) pour une utilisation dans des troubles associés au récepteur de s1p1
MX2019009841A (es) 2017-02-16 2020-01-30 Arena Pharm Inc Compuestos y metodos para el tratamiento de la colangitis biliar primaria.
WO2018187652A1 (en) 2017-04-06 2018-10-11 Janssen Pharmaceutica Nv 2,4-diaminopyrimidine derivatives as histamine h4 modulators
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
CR20200590A (es) 2018-05-04 2021-04-26 Incyte Corp Formas sólidas de un inhibidor de fgfr y procesos para prepararlas
US11174257B2 (en) 2018-05-04 2021-11-16 Incyte Corporation Salts of an FGFR inhibitor
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
WO2021007269A1 (en) 2019-07-09 2021-01-14 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
JP2022552324A (ja) 2019-10-14 2022-12-15 インサイト・コーポレイション Ｆｇｆｒ阻害剤としての二環式複素環
WO2021076728A1 (en) 2019-10-16 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
WO2021104487A1 (en) 2019-11-29 2021-06-03 Aptorum Therapeutics Limited Composition including rilpivirine and use thereof for treating tumors or cancer
US11897891B2 (en) 2019-12-04 2024-02-13 Incyte Corporation Tricyclic heterocycles as FGFR inhibitors
BR112022010664A2 (pt) 2019-12-04 2022-08-16 Incyte Corp Derivados de um inibidor de fgfr
KR102145925B1 (ko) 2020-03-03 2020-08-19 협동조합 바이오융합기술 사포닌 성분이 함유된 항 바이러스용 조성물의 제조방법
CN111875548A (zh) * 2020-07-16 2020-11-03 山东大学 一种5位芳环取代的二芳基嘧啶类衍生物及其制备方法与应用
US11939331B2 (en) 2021-06-09 2024-03-26 Incyte Corporation Tricyclic heterocycles as FGFR inhibitors

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US230963A (en) 1880-08-10 John kobeetson
US2742466A (en) 1956-04-17 Chx n nhx c c
US2671810A (en) 1952-05-24 1954-03-09 Du Pont Long-chain diketones
US2748124A (en) 1954-05-06 1956-05-29 Searle & Co 1-(4-anilino-2-pyrimidino)-3-alkylureas
SU143808A1 (ru) 1961-02-14 1961-11-30 Н.В. Козлова Способ получени 2-хлор-4,6-ди и 2,4,6-три-(2,4-дихлоранилин)-симм. триазинов
GB1010998A (en) 1962-10-09 1965-11-24 British Petroleum Co Pyrimidine derivatives
US3478030A (en) 1966-06-27 1969-11-11 Abbott Lab Benzamide substituted anilino aminopyrimidines
BE754242A (fr) 1970-07-15 1971-02-01 Geigy Ag J R Diamino-s-triazines et dinitro-s-triazines
DE2038182C3 (de) 1970-07-31 1980-10-09 Ciba-Geigy Ag, Basel (Schweiz) 2-Substituierte 4,6-Diamino-stri azine
GB1483271A (en) 1975-03-22 1977-08-17 Ciba Geigy Ag Pigment complexes
GB1477349A (en) 1975-09-24 1977-06-22 Ciba Geigy Ag Azo pigments
US4096206A (en) 1976-02-09 1978-06-20 Borg-Warner Corporation Flame-retardant triazines
FR2400535A1 (fr) 1977-01-27 1979-03-16 Borg Warner Composition de polymere contenant des tris(haloarylamino)triazines ou des tris(haloarylthio)triazines fournissant une aptitude au retardement d'inflammation
FR2398740A1 (fr) 1978-11-06 1979-02-23 Borg Warner Compose fournissant une aptitude au retardement d'inflammation dans un polymere
JPS57203072A (en) 1981-06-05 1982-12-13 Sankyo Co Ltd 4-anilinopyrimidine derivative, its preparation, antidepressant comprising it as active ingredient
US4659363A (en) 1983-07-25 1987-04-21 Ciba-Geigy Corporation N-(2-nitrophenyl)-2-aminopyrimidine derivatives, the preparation and use thereof
US4652645A (en) 1983-11-16 1987-03-24 Ciba-Geigy Corporation Cationic compounds
ATE60591T1 (de) 1984-06-25 1991-02-15 Ciba Geigy Ag Pyrimidinderivate wirksam als schaedlingsbekaempfungsmittel.
JPH0784445B2 (ja) * 1986-12-03 1995-09-13 クミアイ化学工業株式会社 ピリミジン誘導体および農園芸用殺菌剤
ES2013664A6 (es) 1988-03-31 1990-05-16 Mitsubishi Chem Ind Un procedimiento para preparar derivados de nucleosidos de aciclopiramidina sustituidos en la posicion 6.
JPH0252360A (ja) 1988-08-15 1990-02-21 Fujitsu Ltd 電子写真感光体
US4980371A (en) 1988-12-21 1990-12-25 Merrell Dow Pharmaceuticals Antiretroviral furan ketones
DE59010042D1 (de) 1989-03-22 1996-02-22 Ciba Geigy Ag Schädlingsbekämpfungsmittel
IE63502B1 (en) 1989-04-21 1995-05-03 Zeneca Ltd Aminopyrimidine derivatives useful for treating cardiovascular disorders
JPH02300264A (ja) 1989-05-16 1990-12-12 Fuji Photo Film Co Ltd アミノピリミジンアゾメチン色素とその製造方法
JPH02308248A (ja) 1989-05-24 1990-12-21 Fuji Photo Film Co Ltd アミノピリミジン系色素形成カプラーおよび該カプラーを含有するハロゲン化銀カラー写真感光材料
US5064963A (en) 1990-04-25 1991-11-12 American Cyanamid Company Process for the synthesis of n-(3-(1h-imidazol-1-yl)phenyl-4-(substituted)-2-pyrimidinamines
GB9012592D0 (en) 1990-06-06 1990-07-25 Smithkline Beecham Intercredit Compounds
IE75693B1 (en) 1990-07-10 1997-09-10 Janssen Pharmaceutica Nv HIV-inhibiting benzeneacetamide derivatives
JPH04159381A (ja) 1990-10-23 1992-06-02 Arakawa Chem Ind Co Ltd ロジンエステルの製造方法
EP0541966A3 (en) 1991-11-15 1994-09-07 American Cyanamid Co Process for preparing amide derivatives from halomines and acid halides
US5283274A (en) 1992-06-19 1994-02-01 Uniroyal Chemical Company, Inc. Substituted pyrimidines and substituted triazines as rubber-to-metal adhesion promoters
TW234077B (hu) 1992-07-17 1994-11-11 Shell Internat Res Schappej B V
US5516775A (en) 1992-08-31 1996-05-14 Ciba-Geigy Corporation Further use of pyrimidine derivatives
SG49651A1 (en) 1993-02-22 1998-06-15 Janssen Pharmaceutica Nv Method of reversing resistance of hiv-1 strains to zidovudine
HUT74464A (en) 1993-10-12 1996-12-30 Du Pont Merck Pharma 1n-alkyl-n-arylpyrimidinamines and derivatives thereof, and pharmaceutical compositions containing them
CN1142817A (zh) 1993-10-12 1997-02-12 杜邦麦克制药有限公司 1n-烷基-n-芳基嘧啶胺及其衍生物
GB9325217D0 (en) 1993-12-09 1994-02-09 Zeneca Ltd Pyrimidine derivatives
DE19509807A1 (de) * 1995-03-21 1996-09-26 Basf Ag Verfahren zur Herstellung von Wirkstoffzubereitungen in Form einer festen Lösung des Wirkstoffs in einer Polymermatrix sowie mit diesem Verfahren hergestellte Wirkstoffzubereitungen
TW530047B (en) 1994-06-08 2003-05-01 Pfizer Corticotropin releasing factor antagonists
IL114208A0 (en) 1994-06-27 1995-10-31 Merck & Co Inc Combinations of compounds pharmaceutical compositions containing them and their use as hiv protease inhibitors
TW401303B (en) 1994-07-01 2000-08-11 Janssen Pharmaceutica Nv Anti-HIV triple combination
US5574040A (en) 1995-01-06 1996-11-12 Picower Institute For Medical Research Pyrimidine compounds and methods of use to derivatize neighboring lysine residues in proteins under physiologic conditions
JP3691101B2 (ja) 1995-01-24 2005-08-31 三洋電機株式会社 有機エレクトロルミネッセンス素子
DE19504832A1 (de) * 1995-02-14 1996-08-22 Basf Ag Feste Wirkstoff-Zubereitungen
US5691364A (en) 1995-03-10 1997-11-25 Berlex Laboratories, Inc. Benzamidine derivatives and their use as anti-coagulants
JPH09101590A (ja) 1995-07-28 1997-04-15 Fuji Photo Film Co Ltd ハロゲン化銀カラー写真感光材料およびその包装体
US5837436A (en) 1995-07-28 1998-11-17 Fuji Photo Film Co., Ltd. Silver halide color photographic material and package thereof
JPH0968784A (ja) 1995-08-31 1997-03-11 Fuji Photo Film Co Ltd ハロゲン化銀カラー写真感光材料
JPH0980676A (ja) 1995-09-13 1997-03-28 Fuji Photo Film Co Ltd ハロゲン化銀カラー写真感光材料およびその包装体
GB9519197D0 (en) 1995-09-20 1995-11-22 Affinity Chromatography Ltd Novel affinity ligands and their use
GB9523675D0 (en) 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
CN1163401A (zh) 1996-02-13 1997-10-29 李占元 全自动血球计数仪试剂及配制方法
GB9619284D0 (en) 1996-09-16 1996-10-30 Celltech Therapeutics Ltd Chemical compounds
NO311614B1 (no) * 1996-10-01 2001-12-17 Janssen Pharmaceutica Nv Substituerte diamino-1,3,5-triazinderivater
GB9705361D0 (en) 1997-03-14 1997-04-30 Celltech Therapeutics Ltd Chemical compounds
EP0872233A1 (en) 1997-04-14 1998-10-21 Janssen Pharmaceutica N.V. Antiretroviral compositions with improved bioavailability
JPH11116555A (ja) 1997-10-14 1999-04-27 Ube Ind Ltd ４−アニリノピリミジン誘導体及びそれを有効成分とする農園芸用の殺虫・殺ダニ・殺菌剤
AU748087B2 (en) 1998-02-17 2002-05-30 Tularik Inc. Anti-viral pyrimidine derivatives
DE69905306T2 (de) 1998-03-27 2003-11-27 Janssen Pharmaceutica Nv HIV hemmende Pyrimidin Derivate
DE69943247D1 (de) * 1998-03-27 2011-04-14 Janssen Pharmaceutica Nv HIV hemmende Pyrimidin Derivate
EP0945442A1 (en) 1998-03-27 1999-09-29 Janssen Pharmaceutica N.V. Trisubstituted pyrimidine derivatives
EP0945447A1 (en) 1998-03-27 1999-09-29 Janssen Pharmaceutica N.V. Trisubstituted 1,3,5-triazine derivatives for treatment of HIV infections
JP2000111191A (ja) 1998-08-04 2000-04-18 Tokyo Gas Co Ltd 吸収冷温水機
NZ511116A (en) 1998-11-10 2003-08-29 Janssen Pharmaceutica Nv HIV replication inhibiting pyrimidines
US6876717B1 (en) * 2004-08-19 2005-04-05 Intel Corporation Multi-stage programmable Johnson counter

Also Published As

Publication number Publication date
SI1225874T1 (sl) 2006-06-30
AU7512700A (en) 2001-04-30
DE60025837D1 (de) 2006-04-13
AU2004224973B2 (en) 2005-08-25
EP1225874A1 (en) 2002-07-31
TR200200763T2 (tr) 2003-09-22
HK1048768B (zh) 2006-08-04
US20100172970A1 (en) 2010-07-08
AP1639A (en) 2006-07-24
CA2384188A1 (en) 2001-04-05
KR100820605B1 (ko) 2008-04-08
US20060127487A1 (en) 2006-06-15
EE200200151A (et) 2003-04-15
SK285240B6 (sk) 2006-09-07
HRP20020247B1 (en) 2011-02-28
IS6256A (is) 2002-01-31
ZA200202289B (en) 2003-08-27
BR0014271A (pt) 2002-05-21
BRPI0014271B1 (pt) 2021-06-22
JP2003510264A (ja) 2003-03-18
SK3762002A3 (en) 2002-09-10
KR100785360B1 (ko) 2007-12-18
NO333358B1 (no) 2013-05-13
DK1225874T3 (da) 2006-06-12
AU2004224973A1 (en) 2004-11-25
ES2258018T3 (es) 2006-08-16
DE60025837T2 (de) 2006-11-02
EA005423B1 (ru) 2005-02-24
EP1225874B1 (en) 2006-02-01
NO20021443D0 (no) 2002-03-22
PL354026A1 (en) 2003-12-15
AU775360B2 (en) 2004-07-29
HK1048768A1 (en) 2003-04-17
CA2384188C (en) 2008-06-17
IS2567B (is) 2009-12-15
OA12029A (en) 2006-04-28
WO2001022938A1 (en) 2001-04-05
CY1105268T1 (el) 2010-03-03
NO20021443L (no) 2002-03-22
CZ2002907A3 (cs) 2002-05-15
EE04991B1 (et) 2008-04-15
KR20020063847A (ko) 2002-08-05
PL207590B1 (pl) 2011-01-31
ATE316781T1 (de) 2006-02-15
CN1234347C (zh) 2006-01-04
HU228449B1 (en) 2013-03-28
BG65754B1 (bg) 2009-10-30
US20070196478A1 (en) 2007-08-23
US7887845B2 (en) 2011-02-15
AU2004224973C1 (en) 2006-06-01
UA74797C2 (uk) 2006-02-15
CN1376057A (zh) 2002-10-23
BG106521A (bg) 2002-12-29
EA200200401A1 (ru) 2002-10-31
JP4919566B2 (ja) 2012-04-18
US7241458B1 (en) 2007-07-10
AP2002002482A0 (en) 2002-06-30
HUP0203568A3 (en) 2006-07-28
MXPA02003182A (es) 2002-09-30
KR20070036805A (ko) 2007-04-03
PT1225874E (pt) 2006-06-30
CZ300712B6 (cs) 2009-07-22
HRP20020247A2 (en) 2004-04-30
NZ517025A (en) 2003-07-25
IL148801A0 (en) 2002-09-12

Similar Documents

Publication Publication Date Title
HUP0203568A2 (hu) Vírusellenes készítmények
HUP9901144A2 (hu) Hatóanyagként klopidogrel és egy antitrombotikum új kombinációját tartalmazó gyógyszerkészítmények
IL143512A (en) Azabicycloalkanes, pharmaceuticals including them and their use in the manufacture of drugs for the prevention or treatment of infection by the immunodeficiency virus
HUP9900391A2 (hu) Rapamicineket tartalmazó gyógyszerkészítmények
HUP0400850A2 (hu) Orálisan adagolható gyógyászati készítmények
ATE429210T1 (de) Orale flüssige zusammensetzungen
DE69934135D1 (de) Dosierungsformen enthaltend geschmacksmaskierten wirkstoffen
DE69931930D1 (de) Verbindungen und zusammensetzungen zur verabreichung aktiven substanzen
HUP9700603A1 (hu) Gyógyászati készítmény véralvadási zavarok kezelésére
BR9706897A (pt) Composições antifúngicas com biodisponibilidade aperfeiçoada.
EP1291013A3 (de) Lagerfähige Wirkstoffformulierungen
HUP0101564A2 (hu) Epotilon készítmények
BR0008059A (pt) Composições de valdecoxib
BG66093B1 (bg) Състави с контролирано освобождаване, съдържащи нимесулид
DE60334773D1 (de) Formulierungen zur oralen verabreichung von wirkstoffen
SE9201628D0 (sv) Pharmaceutical composition
CA2343732A1 (en) Substituted .gamma.-phenyl-.delta.-lactones and analogs thereof and uses related thereto
PL360254A1 (en) Pharmaceutical compositions
FR2764889B1 (fr) Nouveaux derives du 2-(iminomethyl)amino-phenyle, leur preparation, leur application a titre de medicaments et les compositions pharmaceutiques les contenant
HUP0300848A2 (hu) Kamptotecint és egy pirimidinszármazékot tartalmazó készítmény rák kezelésére
DE68909100D1 (de) Physiologisch wirkende Substanzen, Verfahren zu ihrer Herstellung und pharmazeutische Zusammensetzungen davon.
ATE410148T1 (de) Pharmazeutische zubereitung zur oralen verwendung von heparin und seinen derivaten
DE60202590D1 (de) 2h-1-benzopyran-derivate, prozesse zu ihrer herstellung und pharmazeutische zusammensetzungen
DE69921486D1 (de) Dextran-leptin konjugate, pharmazeutische zusammentsetzungen und verbundene verfahren
HUP0000344A2 (hu) Lamivudint és zidovudint tartalmazó gyógyszerkészítmények